EUVIMEDEUVIMED entdecken
Crossref

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia

Zi-Xuan Wang, Xiao-Long Jing, Qian Liu, Tong Xian, Jin Yang, Meng-Yuan Zhang, Qing-Qing Li, Jiao Cai, Yan-Cheng Yu iD, Shan-Liang Sun, Nian-Guang Li iD, Zhi-Hao Shi

Journal of Medicinal Chemistry · 23.04.2026 · 69 (8) · 9635-9663

DOI: 10.1021/acs.jmedchem.6c00511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.04.2026. Verfasst von Zi-Xuan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing Univer…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine, State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsMutationMiceStructure-Activity RelationshipCell Line, TumorApoptosisDrug DiscoveryCysteine

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase InhibitorsAntineoplastic AgentsCysteine

Autor:innen und Institutionen

  • National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, C…
  • Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China.

ORCID-Profile: Yan-Cheng Yu, Nian-Guang Li

Förderung

  • Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine
  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture

Zitieren

APA

Wang, Z. X., Jing, X. L., Liu, Q., Xian, T., Yang, J., Zhang, M. Y., Li, Q. Q., Cai, J., Yu, Y. C., Sun, S. L., Li, N. G., & Shi, Z. H. (2026). Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 69(8), 9635-9663. https://doi.org/10.1021/acs.jmedchem.6c00511

Vancouver

Wang ZX, Jing XL, Liu Q, Xian T, Yang J, Zhang MY, et al. Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2026;69(8):9635-9663. doi:10.1021/acs.jmedchem.6c00511

BibTeX
@article{Wang2026,
  author = {Wang, Zi-Xuan and Jing, Xiao-Long and Liu, Qian and Xian, Tong and Yang, Jin and Zhang, Meng-Yuan and Li, Qing-Qing and Cai, Jiao and Yu, Yan-Cheng and Sun, Shan-Liang and Li, Nian-Guang and Shi, Zhi-Hao},
  title = {Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {8},
  pages = {9635--9663},
  doi = {10.1021/acs.jmedchem.6c00511}
}
Kostenlos starten →